Aligos Therapeutics Inc
NASDAQ:ALGS

Watchlist Manager
Aligos Therapeutics Inc Logo
Aligos Therapeutics Inc
NASDAQ:ALGS
Watchlist
Price: 20.04 USD 1.26% Market Closed
Market Cap: 71.9m USD
Have any thoughts about
Aligos Therapeutics Inc?
Write Note

Intrinsic Value

ALGS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ALGS stock under the Base Case scenario is 13.75 USD. Compared to the current market price of 20.04 USD, Aligos Therapeutics Inc is Overvalued by 31%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ALGS Intrinsic Value
13.75 USD
Overvaluation 31%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Aligos Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ALGS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ALGS?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Aligos Therapeutics Inc

Provide an overview of the primary business activities
of Aligos Therapeutics Inc.

What unique competitive advantages
does Aligos Therapeutics Inc hold over its rivals?

What risks and challenges
does Aligos Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Aligos Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aligos Therapeutics Inc.

Provide P/S
for Aligos Therapeutics Inc.

Provide P/E
for Aligos Therapeutics Inc.

Provide P/OCF
for Aligos Therapeutics Inc.

Provide P/FCFE
for Aligos Therapeutics Inc.

Provide P/B
for Aligos Therapeutics Inc.

Provide EV/S
for Aligos Therapeutics Inc.

Provide EV/GP
for Aligos Therapeutics Inc.

Provide EV/EBITDA
for Aligos Therapeutics Inc.

Provide EV/EBIT
for Aligos Therapeutics Inc.

Provide EV/OCF
for Aligos Therapeutics Inc.

Provide EV/FCFF
for Aligos Therapeutics Inc.

Provide EV/IC
for Aligos Therapeutics Inc.

Show me price targets
for Aligos Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Aligos Therapeutics Inc?

How accurate were the past Revenue estimates
for Aligos Therapeutics Inc?

What are the Net Income projections
for Aligos Therapeutics Inc?

How accurate were the past Net Income estimates
for Aligos Therapeutics Inc?

What are the EPS projections
for Aligos Therapeutics Inc?

How accurate were the past EPS estimates
for Aligos Therapeutics Inc?

What are the EBIT projections
for Aligos Therapeutics Inc?

How accurate were the past EBIT estimates
for Aligos Therapeutics Inc?

Compare the revenue forecasts
for Aligos Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aligos Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aligos Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aligos Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Aligos Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Aligos Therapeutics Inc with its peers.

Analyze the financial leverage
of Aligos Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Aligos Therapeutics Inc.

Provide ROE
for Aligos Therapeutics Inc.

Provide ROA
for Aligos Therapeutics Inc.

Provide ROIC
for Aligos Therapeutics Inc.

Provide ROCE
for Aligos Therapeutics Inc.

Provide Gross Margin
for Aligos Therapeutics Inc.

Provide Operating Margin
for Aligos Therapeutics Inc.

Provide Net Margin
for Aligos Therapeutics Inc.

Provide FCF Margin
for Aligos Therapeutics Inc.

Show all solvency ratios
for Aligos Therapeutics Inc.

Provide D/E Ratio
for Aligos Therapeutics Inc.

Provide D/A Ratio
for Aligos Therapeutics Inc.

Provide Interest Coverage Ratio
for Aligos Therapeutics Inc.

Provide Altman Z-Score Ratio
for Aligos Therapeutics Inc.

Provide Quick Ratio
for Aligos Therapeutics Inc.

Provide Current Ratio
for Aligos Therapeutics Inc.

Provide Cash Ratio
for Aligos Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Aligos Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Aligos Therapeutics Inc?

What is the current Free Cash Flow
of Aligos Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Aligos Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Aligos Therapeutics Inc

Current Assets 79.8m
Cash & Short-Term Investments 74.9m
Other Current Assets 4.9m
Non-Current Assets 8.6m
PP&E 8m
Other Non-Current Assets 635k
Current Liabilities 21m
Accounts Payable 2.7m
Accrued Liabilities 14.8m
Other Current Liabilities 3.4m
Non-Current Liabilities 17.4m
Long-Term Debt 188k
Other Non-Current Liabilities 17.2m
Efficiency

Earnings Waterfall
Aligos Therapeutics Inc

Revenue
6m USD
Operating Expenses
-100.6m USD
Operating Income
-94.6m USD
Other Expenses
17.6m USD
Net Income
-77m USD

Free Cash Flow Analysis
Aligos Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ALGS Profitability Score
Profitability Due Diligence

Aligos Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

Positive 3-Years Revenue Growth
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
15/100
Profitability
Score

Aligos Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

ALGS Solvency Score
Solvency Due Diligence

Aligos Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
63/100
Solvency
Score

Aligos Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALGS Price Targets Summary
Aligos Therapeutics Inc

Wall Street analysts forecast ALGS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALGS is 68.85 USD with a low forecast of 60.6 USD and a high forecast of 78.75 USD.

Lowest
Price Target
60.6 USD
202% Upside
Average
Price Target
68.85 USD
244% Upside
Highest
Price Target
78.75 USD
293% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ALGS?

Click here to dive deeper.

Dividends

Aligos Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ALGS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ALGS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Aligos Therapeutics Inc Logo
Aligos Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

69.1m USD

Dividend Yield

0%

Description

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2020-10-16. The firm is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. The company uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. The company is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). The company developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The firm's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

Contact

CALIFORNIA
South San Francisco
One Corporate Dr., 2Nd Floor, 2nd Floor
+18004666059.0
www.aligos.com

IPO

2020-10-16

Employees

93

Officers

CEO, President & Chairman of the Board
Dr. Lawrence M. Blatt MBA, Ph.D.
Executive VP & Chief Scientific Officer
Dr. Julian A. Symons DPHIL
Executive VP & CFO
Ms. Lesley Ann Calhoun CPA
VP and Head of People & Culture
Kristina Engeseth
Executive Vice President & Chief Development Officer
Dr. Sushmita M. Chanda DABT, Ph.D.
Executive VP & Head of Chemical Operations
Dr. David B. Smith Ph.D.
Show More
VP of Early Compound Development & Belgian Site Head
Dr. Tse-I Lin Ph.D.
Chief Medical Officer
Dr. Hardean E. Achneck M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ALGS stock?

The intrinsic value of one ALGS stock under the Base Case scenario is 13.75 USD.

Is ALGS stock undervalued or overvalued?

Compared to the current market price of 20.04 USD, Aligos Therapeutics Inc is Overvalued by 31%.

Back to Top